Research Library › GHRH & Ghrelin-Receptor
Sermorelin is a synthetic peptide that reproduces the first 29 amino acids of human growth hormone-releasing hormone, a fragment known as GHRH(1-29) or GRF(1-29). It traces back to the 1982 isolation of GHRH by two Salk Institute teams and was marketed by Serono as Geref. As of 22 Oct 2026, no FDA-approved sermorelin product is sold; Geref was discontinued in 2008, and FDA determined in 2013 that it was not withdrawn for reasons of safety or effectiveness.
Key facts
| Type | Synthetic 29-amino-acid peptide (sermorelin acetate) |
|---|---|
| Derived from | Human GHRH, residues 1–29 |
| First described | 1982, Salk Institute (Guillemin and Vale laboratories) |
| Developed by | Marketed as Geref by Serono |
| Designed target | GHRH receptors on the anterior pituitary |
| Regulatory status (Oct 2026) | Formerly FDA-approved; discontinued 2008; FDA 2013: not withdrawn for safety or effectiveness; not on FDA Category 2 list; named on WADA 2026 list (S2) |
Who developed it
Sermorelin rests on one of the notable races in endocrinology. In 1982, two teams at the Salk Institute in La Jolla, California, independently identified human GHRH: one led by Roger Guillemin, the other by Wylie Vale, working with Michael Thorner of the University of Virginia [1][2]. Guillemin had shared the 1977 Nobel Prize in Physiology or Medicine for earlier work on hypothalamic hormones such as TRH and somatostatin [4][5].
The finished drug, Geref, was marketed by Serono [6][7].
What it was designed to target
Natural GHRH is a 44-amino-acid peptide made in the hypothalamus. In its 1982 report, Vale’s team found that a shortened piece containing only the first 29 amino acids kept the full peptide’s activity in laboratory assays [2]. Sermorelin is that 29-residue fragment.
It is designed to bind GHRH receptors on the anterior pituitary, the same receptors targeted by the natural hormone [2][7].
Why it was created
Both 1982 teams found GHRH not in brain tissue but in pancreatic tumors that produced it in excess [1][2]. One clue came from a single case: Thorner and colleagues described a young woman with acromegaly whose condition was traced to a pancreatic islet tumor secreting a growth hormone-releasing factor [3].
In the United States, Geref was approved first as a diagnostic agent for assessing the pituitary’s capacity to release growth hormone, and later for an indication related to growth failure in children with growth hormone deficiency [7].
Research timeline
- 1977: Guillemin shares the Nobel Prize for work on hypothalamic hormones [4].
- 1982: GHRH is isolated from pancreatic tumors by two Salk teams; the 29-residue fragment is reported to retain activity [1][2].
- 1990: FDA approves Geref as a diagnostic agent [7].
- 1991: Geref is licensed in Ireland [8].
- 1997: FDA approves Geref for a pediatric growth hormone deficiency indication [7].
- 2007: The Irish license is withdrawn [8].
- 2008: EMD Serono stops selling Geref in the U.S. [7].
- 2013: FDA determines Geref was not withdrawn for safety or effectiveness reasons [7].
Regulatory status as of October 2026
As of 22 Oct 2026, no FDA-approved sermorelin product is on the U.S. market. In response to a 2012 citizen petition, FDA determined in March 2013 that Geref was not withdrawn from sale for reasons of safety or effectiveness, which means a generic version referencing it could still be approved in principle [7]. Its former approvals in the United States and Ireland are both retired [7][8].
Sermorelin does not appear on FDA’s April 2026 list of bulk drug substances that may present significant safety risks in compounding (the Category 2 list) [9].
Sermorelin is named on the 2026 World Anti-Doping Agency Prohibited List under S2 as a GHRH analog, prohibited at all times [10].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who discovered sermorelin?
Sermorelin derives from human GHRH, identified in 1982 by two Salk Institute teams led by Roger Guillemin and Wylie Vale. Vale’s team reported that the first 29 amino acids retained the full peptide’s activity in lab tests.
Is sermorelin FDA approved?
Sermorelin was FDA-approved as Geref, but the product was discontinued in 2008. As of 22 Oct 2026 no approved sermorelin product is sold, though FDA ruled in 2013 that Geref was not withdrawn for safety or effectiveness reasons.
What is the difference between sermorelin and GHRH?
Natural GHRH has 44 amino acids. Sermorelin contains only the first 29, the shortest portion shown in 1982 to keep the full peptide’s activity in laboratory assays.
Why was sermorelin discontinued?
EMD Serono stopped selling Geref in 2008. FDA later determined that the withdrawal was not for reasons of safety or effectiveness.
Sources
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982 Nov 5;218(4572):585–587. PMID 6812220. Link
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982 Nov 18;300:276–278. doi:10.1038/300276a0. Link
- Thorner MO, Perryman RL, Cronin MJ, et al., Vale W, Horvath E, Kovacs K. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982;70(5):965–977. Link
- NobelPrize.org. The Nobel Prize in Physiology or Medicine 1977: summary (Guillemin, Schally, Yalow). Link
- Salk Institute. Salk Institute mourns the loss of Nobel laureate Roger Guillemin, distinguished professor emeritus. 23 Feb 2024. Link
- Peri KG, Habi A (Theratechnologies Inc.). Growth hormone releasing factor (GRF) analogs and uses thereof. US Patent 8,361,964 (background describes Geref, hGRF(1-29), marketed by Laboratoires Serono). Link
- U.S. FDA. Response to citizen petition FDA-2012-P-1071 and determination that Geref (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness. Mar 2013; Federal Register 4 Mar 2013. Link
- Health Products Regulatory Authority (Ireland). GEREF 50 (sermorelin acetate), Serono Ltd, PA0285/006/001: licensed 26 Jul 1991, withdrawn 6 Jul 2007. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List (S2.2.4 growth hormone releasing factors; S2.3 growth factors). In force 1 Jan 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
